StockNews.com Upgrades Pulse Biosciences (NASDAQ:PLSE) to Sell

Pulse Biosciences (NASDAQ:PLSE) was upgraded by research analysts at StockNews.com to a “sell” rating in a note issued to investors on Wednesday.

Pulse Biosciences Trading Up 0.3 %

PLSE traded up $0.07 during trading hours on Wednesday, hitting $20.37. The company’s stock had a trading volume of 179,185 shares, compared to its average volume of 202,376. The business’s 50-day moving average price is $17.18 and its 200-day moving average price is $15.60. Pulse Biosciences has a 12 month low of $6.59 and a 12 month high of $22.69.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings data on Wednesday, October 30th. The company reported ($0.21) earnings per share for the quarter. During the same quarter last year, the company posted ($0.19) EPS.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in PLSE. Vanguard Group Inc. grew its holdings in shares of Pulse Biosciences by 28.8% in the first quarter. Vanguard Group Inc. now owns 847,212 shares of the company’s stock worth $7,379,000 after purchasing an additional 189,227 shares during the last quarter. Price T Rowe Associates Inc. MD bought a new position in shares of Pulse Biosciences in the first quarter worth about $88,000. Cetera Advisors LLC bought a new position in shares of Pulse Biosciences in the first quarter worth about $109,000. Westside Investment Management Inc. grew its holdings in shares of Pulse Biosciences by 97.8% in the second quarter. Westside Investment Management Inc. now owns 63,600 shares of the company’s stock worth $712,000 after purchasing an additional 31,440 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in shares of Pulse Biosciences by 23.4% in the second quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company’s stock worth $570,000 after purchasing an additional 9,639 shares during the last quarter. 76.95% of the stock is currently owned by institutional investors.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.